- Home
- PHAR
PHAR
Pharming Group N.V.
as 11-15-2024 4:00pm EST
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
| Founded: | 1988 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 627.5M | IPO Year: | N/A |
| Target Price: | $33.50 | AVG Volume (30 days): | 6.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.65 - $13.20 | Next Earning Date: | 10-24-2024 |
| Revenue: | $285,745,000 | Revenue Growth: | 30.64% |
| Revenue Growth (this year): | 20.89% | Revenue Growth (next year): | 11.15% |
Latest Pharming Group N.V. News
PHAR Breaking Stock News: Dive into PHAR Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Pharming Group to participate in November investor conference
Simply Wall St.
13 days ago
High Growth Tech And 2 Other Promising Stocks To Watch
GuruFocus.com
23 days ago
Pharming Group (PHGUF) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
GlobeNewswire
24 days ago
Pharming Group reports third quarter 2024 financial results and provides business update
Simply Wall St.
a month ago
October 2024's Promising Penny Stocks to Watch
GlobeNewswire
a month ago
Pharming Group to report third quarter 2024 financial results on October 24
Zacks
a month ago
Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last?
MT Newswires
2 months ago
Pharming Group Gets Marketing Approval in UK for Immunodeficiency Drug
Compare PHAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAR Pharming Group N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.